Genotype and risk of major bleeding during warfarin treatment

AIM: To determine whether genetic variants associated with warfarin dose variability were associated with increased risk of major bleeding during warfarin therapy. MATERIALS & METHODS: Using Vanderbilt’s DNA biobank we compared the prevalence of CYP2C9, VKORC1 and CYP4F2 variants in 250 cases wi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pharmacogenomics
Auteurs principaux: Kawai, Vivian K, Cunningham, Andrew, Vear, Susan I, Van Driest, Sara L, Oginni, Abimbola, Xu, Hua, Jiang, Min, Li, Chun, Denny, Joshua C, Shaffer, Christian, Bowton, Erica, Gage, Brian F, Ray, Wayne A, Roden, Dan M, Stein, C Michael
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4304738/
https://ncbi.nlm.nih.gov/pubmed/25521356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs.14.153
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires